Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients.

@article{BorrsBlasco2014ClinicalAE,
  title={Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients.},
  author={Joaqu{\'i}n Borr{\'a}s-Blasco and Antonio Gracia-P{\'e}rez and J Dolores Rosique-Robles and M D Elvira Caster{\'a} and Fatemeh J A Abad},
  journal={Expert opinion on biological therapy},
  year={2014},
  volume={14 2},
  pages={145-50}
}
OBJECTIVE To determine the clinical and economic impact of etanercept 25 mg/week (ETN25) on rheumatoid arthritis (RA), psoriatic arthropathy (PA) and ankylosing spondylitis (AS) patients in sustained clinical remission. METHODS Observational, retrospective cohort of patients treated with etanercept 50 mg/week (ETN50) who achieved and maintained clinical remission (Disease Activity Score 28 < 2.6 or BASDAI < 2) over a period of 1 year and had slow worsening of structural changes were enrolled… CONTINUE READING